#ES­MO22: Trail­ing Roche’s Tecen­triq, im­mune check­point ther­a­pies meet un­treat­ed liv­er can­cer with mixed re­sults

PARIS — In 2020, Roche’s Tecen­triq, a PD-L1 in­hibitor, got an FDA nod in com­bi­na­tion with Avastin for un­treat­ed ad­vanced liv­er can­cer, be­com­ing the first im­mune check­point ther­a­py to make it to the first line for these tu­mors. That ap­proval, deemed a “land­mark,” came on the back of a Phase III tri­al that showed the Tecen­triq com­bo pro­longed sur­vival longer than Nex­avar — the Bay­er drug that had stood un­beat­en as the stan­dard of care in first line liv­er can­cer since 2007.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER